Summary & Overview
CPT 0207T: Thermal and Pressure Treatment for Meibomian Gland Dysfunction
CPT code 0207T denotes a therapeutic ophthalmic procedure using thermal energy combined with pressure to treat meibomian gland dysfunction (MGD), a common cause of evaporative dry eye. The code captures a technology-driven, office- or ambulatory-based intervention aimed at restoring gland expressibility and improving tear film stability. Nationally, this code matters as MGD-related dry eye contributes substantially to patient morbidity, increases outpatient procedure utilization, and has implications for coverage policy and clinical pathway development.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the procedure is defined clinically and operationally, insights into where the service is typically delivered, and expectations for documentation and coding alignment. The publication summarizes available benchmarks and payment context, highlights relevant clinical considerations for patient selection, and outlines common administrative elements associated with billing and claims submission.
This national summary is intended for health policy analysts, billing professionals, and clinical leaders seeking a concise reference on CPT code 0207T, its clinical role in managing dry eye from MGD, and the payer landscape relevant to coverage and reimbursement discussions.
Billing Code Overview
CPT code 0207T describes a procedure in which the provider uses thermal energy and pressure to treat meibomian gland dysfunction that causes dry eye syndrome. The service type is a therapeutic ophthalmic procedure targeting the meibomian glands of the eyelids to restore gland function and improve tear film quality.
The typical site of service for CPT code 0207T is an outpatient ophthalmology or eye care clinic, ambulatory surgical center, or other facility where office-based eye procedures are performed.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents to an ophthalmology clinic with chronic symptoms of ocular irritation, burning, fluctuating vision, and contact lens intolerance despite optimized artificial tears and lid hygiene. The history and ocular surface exam reveal evidence of meibomian gland dysfunction (MGD) with meibomian gland obstruction, lid telangiectasia, frothy tear film, and reduced tear breakup time consistent with evaporative dry eye syndrome. After conservative measures (warm compresses, lid scrubs, omega-3 supplementation) and a trial of topical anti-inflammatory therapy, the clinician elects in-office thermal and expression treatment targeting meibomian gland orifices.
The clinical workflow: the patient is consented and prepped in an outpatient ophthalmology procedure room. Topical anesthesia and antisepsis are applied. A device that applies controlled thermal energy and simultaneous pressure to the eyelids is used to heat meibomian glands and express obstructed contents. The provider documents pre-procedure evaluation, device settings, treatment duration per eye, any complications, and post-procedure instructions. Follow-up visits assess symptom improvement, gland function, and need for repeat treatment. Typical site of service is an outpatient ophthalmology clinic or ambulatory surgery center. Service type is a physician-directed in-office therapeutic procedure for meibomian gland dysfunction using thermal energy and pressure, billed with 0207T.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|